. Scientific Frontline: Galectin-3 Reshapes Plaques in Alzheimer's Disease

Friday, November 20, 2026

Galectin-3 Reshapes Plaques in Alzheimer's Disease

This visual representation of the neural environment during Alzheimer’s disease progression features the key structures involved in the pathology.
Alzheimer's disease (AD) is characterised by accumulations of beta-amyloid (Aβ) in the brain.
Image Credit: Scientific Frontline / AI generated

Scientific Frontline: Extended "At a Glance" Summary
: Role of Galectin-3 in Alzheimer's Disease

The Core Concept: Researchers at Lund University, working with collaborators in Spain, have discovered that the immune-cell protein galectin-3 actively reshapes beta-amyloid (Aβ) plaques in Alzheimer's disease (AD) rather than merely accumulating around them. By binding directly to Aβ fibers and regulating how brain immune cells called microglia process amyloid, galectin-3 drives neuroinflammation and accelerates damage to surrounding nerve cells.

Key Distinction/Mechanism: Galectin-3 binds strongly to Aβ and operates simultaneously in two locations: outside microglia on the plaque surface, where it blocks a step in amyloid fibril multiplication and alters fibril shape, and inside microglial lysosomes, where it directs amyloid breakdown. In cell experiments, these reshaped fibrils damaged nerve cells, whereas removing galectin-3 in mice with an Alzheimer's-like condition produced smaller, more tightly packed plaques, markedly less nerve-ending damage, and a microglial shift from an aggressive state to a protective state rich in the immune receptor TREM2. Unlike existing AD antibody therapies that clear amyloid without curbing brain inflammation, targeting galectin-3 addresses both plaque structure and the damaging immune response.

Origin/History: In a previous study, the Lund University research team demonstrated for the first time that galectin-3 levels increase in the brains of people with AD and that removing the protein reduces brain inflammation. The current research builds on that precedent by revealing the direct physical and cellular mechanisms linking galectin-3 to Aβ plaque architecture and nerve injury.

Major Frameworks/Components:

  • Dual-Site Galectin-3 Activity: Galectin-3 acts concurrently outside microglia to physically remodel growing Aβ fibrils and inside microglial lysosomes to steer intracellular amyloid degradation. This dual localization explains how a single immune protein alters both extracellular plaque structure and cellular clearance pathways.
  • Microglial State Transition and TREM2: Inactivating galectin-3 in mouse models shifts microglia from a harmful, inflammatory phenotype to a protective state enriched in the receptor TREM2. Because TREM2 supports the brain's immune defense and influences AD risk, modulating this transition reduces collateral damage to adjacent nerve endings.
  • Translational Validation Models: Experiments in mice established a clear cause-and-effect relationship among galectin-3 removal, tighter plaque compaction, and reduced nerve-ending injury. Complementary analyses of brain tissue from nine human individuals confirmed a strong correlation with human disease, while cell cultures verified the neurotoxicity of galectin-3-reshaped fibrils.

Branches of Science: Neuroimmunology, Molecular Neurobiology, Neuropathology, Cellular Neurobiology, and Neuropharmacology.

Future Application: Because galectin-3 is a druggable protein capable of binding therapeutic agents, researchers identify it as a promising candidate for future AD treatments targeting both amyloid pathology and neuroinflammation. US regulators recently authorized a phase 2 clinical trial evaluating a galectin-3-blocking antibody derived from the group's earlier findings. Controlled clinical trials will be necessary to establish whether blocking galectin-3 delivers measurable clinical benefits to patients.

Why It Matters: Currently available amyloid-clearing antibody drugs produce only modest clinical effects and do not alleviate the chronic brain inflammation that accompanies AD. Demonstrating that galectin-3 directly shapes toxic Aβ fibrils while steering microglial aggression connects two major drivers of disease progression—protein aggregation and neuroinflammation. Targeting this protein opens a therapeutic pathway that could fill critical gaps left by existing amyloid-focused interventions.

Researchers at Lund University in Sweden have found in mouse models, cell cultures, and human brain tissue that the immune-cell protein galectin-3 actively modifies amyloid plaques in Alzheimer's disease. Rather than only influencing how the brain's resident immune cells, known as microglia, react to these plaques, galectin-3 directly alters plaque structure and may exacerbate damage to surrounding neurons.

"This discovery provides new insights into the mechanisms of the disease and identifies galectin-3 as a potential future therapeutic target," says Lluís Camprubí-Ferrer, one of the study's lead authors and a postdoctoral researcher at Lund University.

Alzheimer's disease is characterized in part by the accumulation of beta-amyloid (Aβ) peptides in the brain, which aggregate to form extracellular plaques. In an earlier study, the Lund University team found elevated galectin-3 levels in the brains of people with Alzheimer's disease and demonstrated in animal models that eliminating the protein reduced neuroinflammation. In this new study, the researchers examined the direct interaction between galectin-3 and Aβ plaques.

The findings indicate that galectin-3 binds strongly to Aβ and operates at two distinct sites. Outside microglia, galectin-3 associates directly with plaques, altering the morphology of growing amyloid fibrils. Inside microglia, it localizes to lysosomes—the cellular organelles that degrade engulfed material—where it regulates how amyloid is processed. Galectin-3, the researchers conclude, is not merely present around the plaque: it actively shapes it.

Although disrupting fibril assembly might appear protective, the team found that the resulting structural changes produced more neurotoxic fibrils in cell culture.

"No one has previously shown what galectin-3 does to the plaque itself. We have observed that the protein binds to long protein strands known as amyloid fibrils, blocking one of the steps by which they multiply and altering their shape. In cell experiments, the fibrils reshaped by galectin-3 went on to damage nerve cells," explains Camprubí-Ferrer.

Conducted in collaboration with the University of Seville and the Instituto de Biomedicina de Sevilla in Spain, the study examined both mouse models of Alzheimer's-like pathology and human brain tissue. When the researchers eliminated galectin-3 in the mice, amyloid plaques became smaller and more compact, adjacent neuronal processes sustained markedly less damage, and microglia shifted from an inflammatory phenotype toward a more protective state.

"When we inactivated galectin-3, microglia transitioned from their harmful state to a state rich in the protective receptor TREM2 [triggering receptor expressed on myeloid cells 2], a protein that we know plays an important role in the brain's immune defense and in the risk of Alzheimer's disease," says Camprubí-Ferrer.

In Alzheimer's pathology, microglial activation spans a complex, context-dependent spectrum of states rather than a simple binary switch, and how these findings translate from animal models to human disease remains an open question. While the mouse experiments establish a causal relationship in an animal model, the human brain tissue analysis—based on a small sample of nine individuals (n = 9)—demonstrates only an association and cannot confirm causality in patients. Whether blocking galectin-3 improves clinical outcomes in people with Alzheimer's disease can be determined only through clinical trials.

Referring to approved anti-amyloid antibody therapies rather than symptomatic Alzheimer's medications, Camprubí-Ferrer notes that existing plaque-targeting treatments do not directly resolve chronic neuroinflammation.

"This is important because current Alzheimer's drugs target amyloid without helping to reduce inflammation in the brain. And galectin-3 is a protein that drugs can actually bind to," he says.

"And the timing is right. Drugs containing antibodies that break down amyloid have reached patients, but their modest effect has drawn attention to the brain's immune response. That is where we can now fill in the gaps," says Tomas Deierborg, professor and leader of the Experimental Neuroinflammation research group at Lund University.

Earlier findings from the group have already informed translational development. In late 2026, the US Food and Drug Administration cleared a phase 2 clinical trial to evaluate an antibody that blocks galectin-3, though safety and efficacy in patients remain unproven.

"This demonstrates the clinical potential of our research findings," says Deierborg.

Funding: Strategic Research Area MultiPark at Lund University, the Swedish Research Council; the Alzheimer Foundation, Olle Engkvist Foundation, the Swedish Brain Foundation, Anna and Edwin Berger Foundation, Greta and Johan Kock Foundations, the Royal Physiographic Society in Lund, the Hans-Gabriel and Alice Trolle-Wachtmeister Foundation for Medical Research, the Crafoord Foundation, the Parkinson Foundation, the Rönström Family Foundation and others.

Published in journal: Proceedings of the National Academy of Sciences of the United States of America

Title: Galectin-3 links microglial neuroinflammation to Aβ aggregation and lysosomal processing

Authors: Lluís Camprubí-Ferrer, Jesús Soldán-Hidalgo, Emil Axell, Marzia Dell’Eva, Marta García-Cruzado, Juan García-Revilla, Yiyi Yang, Rosalía Fernández-Calle, Logan Larlham, Bhanu Chouhan, Rocío Talaverón, Agnes Paulus, Lukas Danielson, Angela Gomez-Arboledas, Oxana Klementieva, Antonia Gutierrez, Javier Vitorica, Malin Wennström, Gunnar K. Gouras, Javier Frontiñán-Rubio, Antonio Boza-Serrano, Gabriel A. Rabinovich, José Luis Venero, Tomas Deierborg

Source/Credit: Lund University | Erika Svantesson

Edited by: Scientific Frontline

Reference Number: imgy112026_01

Privacy Policy | Terms of Service | Contact Us

Featured Article

What Is: The Minimal Genome and Synthetic Evolution

Scientific Frontline: Extended "At a Glance" Summary : The Minimal Genome and Synthetic Evolution The Core Concept : Researchers h...

Top Viewed Articles